The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.
Source link
About The Author
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial